
Andrew Gray

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1348633/publications.pdf Version: 2024-02-01



Δηροείω Οραν

#	Article	IF	CITATIONS
1	Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science, 2010, 329, 1168-1174.	6.0	2,239
2	Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. New England Journal of Medicine, 2010, 362, 697-706.	13.9	608
3	Integration of Antiretroviral Therapy with Tuberculosis Treatment. New England Journal of Medicine, 2011, 365, 1492-1501.	13.9	451
4	25 years of the WHO essential medicines lists: progress and challenges. Lancet, The, 2003, 361, 1723-1729.	6.3	243
5	Shortages of medicines: a complex global challenge. Bulletin of the World Health Organization, 2012, 90, 158-158.	1.5	101
6	The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. The Cochrane Library, 2013, , CD005175.	1.5	84
7	The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. European Journal of Clinical Pharmacology, 2012, 68, 689-695.	0.8	50
8	Enrolling Adolescents in Research on HIV and Other Sensitive Issues: Lessons from South Africa. PLoS Medicine, 2006, 3, e180.	3.9	43
9	Surveillance of community antimicrobial use in resource-constrained settings - experience from five pilot projects. Tropical Medicine and International Health, 2011, 16, 152-161.	1.0	34
10	Surveillance of antimicrobial resistance in resourceâ€constrained settings – experience from five pilot projects. Tropical Medicine and International Health, 2011, 16, 368-374.	1.0	30
11	Home self-testing for HIV: AIDS exceptionalism gone wrong. South African Medical Journal, 2010, 100, 636.	0.2	27
12	A Model for Estimating Individualized Valproate Clearance Values in Children. Journal of Clinical Pharmacology, 1995, 35, 1020-1024.	1.0	22
13	A model for the determination of carbamazepine clearance in children on mono- and polytherapy. European Journal of Clinical Pharmacology, 1998, 54, 359-362.	0.8	16
14	Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opinion on Drug Safety, 2011, 10, 559-574.	1.0	16
15	Counting the costs: Comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa. BMC Health Services Research, 2001, 1, 4.	0.9	13
16	The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. South African Medical Journal, 2010, 100, 808.	0.2	10
17	Cost-Effectiveness of Initiating Antiretroviral Therapy at Different Points in TB Treatment in HIV-TB Coinfected Ambulatory Patients in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 576-584.	0.9	10
18	Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis–HIV-co-infected patients in resource-constrained settings. Aids, 2006, 20, 302-303.	1.0	9

ANDREW GRAY

#	Article	IF	CITATIONS
19	Setting standards for essential children's medicines. Bulletin of the World Health Organization, 2007, 85, 650-650.	1.5	9
20	Tough choices: Tenofovir, tenders and treatment. Southern African Journal of HIV Medicine, 2008, 9, 8.	0.3	9
21	Conference conclusions. American Journal of Health-System Pharmacy, 2009, 66, s75-s76.	0.5	2
22	WHO Essential Medicines List for Children. Paediatric Drugs, 2011, 13, 209-211.	1.3	2
23	Hormone therapy use in the South African public and private sectors 2001–2005. Maturitas, 2008, 60, 182-184.	1.0	1
24	The challenges of implementing antiretroviral treatment in South Africa. , 0, , 551-566.		1
25	Teaching pharmaceutical care principles for PHC. Medical Teacher, 1998, 20, 460-463.	1.0	Ο
26	Conference welcome. American Journal of Health-System Pharmacy, 2009, 66, s8-s9.	0.5	0